Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Sandra Rebouissou Clear advanced filters

  • Paediatric liver cancer is rare, and often associated with a predisposition syndrome. Here, the authors show that 11p15.5 mosaic alteration in the liver is a pre-neoplastic lesion associated with hepatoblastoma, and spatial transcriptomics together with single-nucleus RNAseq identify a an altered zonation in the liver of these patients.

    • Jill Pilet
    • Theo Z. Hirsch
    • Jessica Zucman-Rossi
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-14

  • Activation of the PPARγ/RXRα pathway in luminal bladder cancers has mainly been linked to PPARG gene amplifications and activating point mutations in RXRα. Here, the authors identify recurrent PPARγ mutations with similar effects and elucidate the structural basis for this mutational PPARγ activation.

    • Natacha Rochel
    • Clémentine Krucker
    • Isabelle Bernard-Pierrot
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-12

  • Inflammatory heptocellular adenomas (IHCAs) show activation of an acute-phase inflammatory response signalling pathways, and it is found that this is due to gain-of function mutations in the IL6ST gene encoding gp130, a coreceptor for IL-6 and other cytokines that activate inflammatory signalling pathways. These mutations lead to constitutive activation of STAT3 signalling, contributing to the inflammatory phenotype of IHACs.

    • Sandra Rebouissou
    • Mohamed Amessou
    • Jessica Zucman-Rossi
    Research
    Nature
    Volume: 457, P: 200-204

  • Jessica Zucman-Rossi and colleagues report exome sequences of 243 hepatocellular carcinomas. They identify mutational signatures associated with specific risk factors such as alcohol, tobacco and aflatoxin B1 and find genetic alterations potentially targetable by FDA-approved drugs in 28% of the tumors.

    • Kornelius Schulze
    • Sandrine Imbeaud
    • Jessica Zucman-Rossi
    Research
    Nature Genetics
    Volume: 47, P: 505-511

  • Telomerase is a key enzyme for cell survival that prevents telomere shortening. In this Review, the roles of telomeres and telomerase in cirrhosis and liver carcinogenesis are discussed, in addition to their potential in clinical practice as biomarkers and therapeutic targets.

    • Jean-Charles Nault
    • Massih Ningarhari
    • Jessica Zucman-Rossi
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 16, P: 544-558